Loading cancer entity…
Loading cancer entity…
Clinical trials
8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,291)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00558727 |
| Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
| terminated |
| Phase 1 |
| 12 |
| Spectrum Pharmaceuticals, IncINDUSTRY |
| 1 |
| May 10, 2013 |
| clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01292486 | Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure | completed | N/A | 32 | Terumo BCTINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | completed | Phase 2 | 55 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 29, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01268774 | Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. | completed | — | 529 | LEO PharmaINDUSTRY | 0 | Apr 18, 2013 | clinicaltrials |
| NCT00440635 | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma | completed | — | 641 | Janssen-Cilag International NVINDUSTRY | 0 | Apr 16, 2013 | clinicaltrials |
| NCT01830478 | Lenalidomide Plus Rituximab (R) in Non Follicular NHL | unknown | Phase 2 | 44 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT01829412 | Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma(MMY-MRI-08) | completed | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Apr 11, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT01813344 | Hyper-CVAD Treatment in Lymphoblastic Lymphoma(LBL-CISL-1) | unknown | — | 50 | Ajou University School of MedicineOTHER | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | terminated | Phase 2 | 5 | SymBio PharmaceuticalsINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT01030302 | A Retreatment Study With Bortezomib for Multiple Myeloma | completed | — | 56 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Mar 8, 2013 | clinicaltrials |
| NCT01806337 | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | completed | Phase 2 | 41 | University of GöttingenOTHER | 0 | Mar 7, 2013 | clinicaltrials |
| NCT01278602 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | terminated | Phase 2 | 4 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667302 | Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | unknown | Phase 2 | 196 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00002649 | Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 3 | 206 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00283985 | Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma | completed | Phase 2 | 40 | University Hospital, LimogesOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00003204 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 3 | 515 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT01396200 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | completed | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT01005628 | Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) | completed | — | 1,121 | Janssen Korea, Ltd., KoreaINDUSTRY | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Feb 20, 2013 | clinicaltrials |
| NCT00521560 | A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas(escZ-BEAM) | completed | Phase 2 | 28 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01074060 | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT01660568 | Gemcitabine in NK/T Cell Lymphoma | completed | — | 20 | Samsung Medical CenterOTHER | 1 | Feb 13, 2013 | clinicaltrials |
| NCT00428545 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | completed | Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00959686 | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma(BENTLY) | completed | Phase 2 | 45 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00310024 | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00062621 | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | completed | Phase 1 | 5 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00114348 | ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia | completed | Phase 4 | 338 | Charite University, Berlin, GermanyOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | terminated | N/A | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2013source: clinicaltrials